Savara (NASDAQ:SVRA) Stock Price Up 6%

Shares of Savara Inc (NASDAQ:SVRA) traded up 6% during trading on Monday . The company traded as high as $4.45 and last traded at $4.45. 1,005,176 shares traded hands during trading, a decline of 16% from the average session volume of 1,195,491 shares. The stock had previously closed at $4.20.

Analyst Ratings Changes

SVRA has been the subject of a number of research analyst reports. Oppenheimer upped their price target on shares of Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 26th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Savara in a research report on Wednesday, August 14th. JMP Securities reiterated a “market outperform” rating and set a $9.00 price target on shares of Savara in a research report on Monday, September 9th. Finally, Guggenheim raised their target price on Savara from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $11.17.

Savara Stock Up 2.9 %

The company has a debt-to-equity ratio of 0.26, a quick ratio of 11.31 and a current ratio of 11.31. The stock has a market cap of $596.98 million, a price-to-earnings ratio of -11.43 and a beta of 0.97. The business’s 50 day moving average is $4.42 and its 200 day moving average is $4.52.

Savara (NASDAQ:SVRA) last released its earnings results on Monday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). Equities analysts expect that Savara Inc will post -0.44 earnings per share for the current year.

Hedge Funds Weigh In On Savara

Several institutional investors and hedge funds have recently bought and sold shares of the business. ProShare Advisors LLC lifted its position in shares of Savara by 9.0% in the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock worth $128,000 after purchasing an additional 2,114 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Savara by 15.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company’s stock valued at $168,000 after buying an additional 4,625 shares during the period. The Manufacturers Life Insurance Company lifted its position in Savara by 14.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 41,250 shares of the company’s stock worth $166,000 after buying an additional 5,335 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of Savara by 64.4% during the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after buying an additional 6,973 shares during the period. Finally, CANADA LIFE ASSURANCE Co purchased a new position in shares of Savara during the 1st quarter valued at $35,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.